Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802772
  • Report
  • 39 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • Novartis AG
  • Redx Pharma Plc
  • MORE
Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1)
- The report reviews Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • Novartis AG
  • Redx Pharma Plc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Overview

Therapeutics Development

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Stage of Development

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Therapy Area

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Indication

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Companies

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Basilea Pharmaceutica AG

Eli Lilly and Company

Millennium Pharmaceuticals, Inc.

Novartis AG

Redx Pharma Plc

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Drug Profiles

BAL-3833 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXH-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3009120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-580 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Dormant Projects

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Featured News & Press Releases

Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting

Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting

Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting

Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015

Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120

Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors

Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec

Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 3List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Basilea Pharmaceutica AG, H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Redx Pharma Plc, H1 2016

Dormant Projects, H1 2016 32List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • Novartis AG
  • Redx Pharma Plc
  • MORE
Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Serine/threonine-protein kinase A-Raf is an enzyme that in humans is encoded by the ARAF gene. Ii is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It regulates the TOR signaling cascade.

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1 and 1 respectively.

The author's latest report SerineThreonine-Protein Kinase A-Raf - Pipeline Review, H1 2016, outlays comprehensive information on the Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Basilea Pharmaceutica AG
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Novartis AG
Redx Pharma Plc
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll